This year, we were proud to award new research grants supporting truly cutting-edge projects. We also know that smarter research funding is just one part of the solution, and that long-term impact will require strategic collaboration among all members of the pediatric cancer ecosystem: academia, pharma, regulatory agencies, funders, and the patient community.
With the expert leadership of our Industry and Scientific Advisory Councils, we’re uniquely positioned to drive the collaborations needed to address the barriers and deliver the new, better treatments that our kids deserve. Highlights include:
- The inaugural CureSearch Pediatric Early Development Symposium, where global leaders in pediatric oncology shared lessons and collaborative solutions to address challenges in pediatric oncology study development
- A new initiative with the Milken Institute’s FasterCures and Children’s Tumor Foundation to identify and revitalize promising but discontinued drugs with pediatric potential
- The 2021 CureSearch Summit Series: The State of Pediatric Solid Tumor Biopsies, a four-part virtual meeting addressing the limited biopsy availability and accessibility to improve therapy options for pediatric patients
As the year draws to a close, please consider making a tax-deductible donation to help drive these innovative and critical collaborations forward into 2021. With your support, we can bring our kids to the forefront of drug development and deliver better treatment options to those who need them most.
